E Rosenthal

Summary

Country: France

Publications

  1. pmc Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)
    Dominique Salmon-Ceron
    Unité de maladies infectieuses, Pôle Médecine, Hopital Cochin, Paris, France
    BMC Health Serv Res 12:59. 2012
  2. pmc The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010
    Marc Arthur Loko
    INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
    BMC Infect Dis 10:303. 2010
  3. doi request reprint [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009]
    E Rosenthal
    Service de Medecine Interne, centre hospitalier universitaire de Nice et université de Nice Sophia Antipolis, France
    Med Mal Infect 39:741-4. 2009
  4. doi request reprint Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19)
    E Rosenthal
    Department of Internal Medicine, Archet Hospital Centre, University of Nice Sophia Antipolis, Nice, France
    HIV Med 10:282-9. 2009
  5. ncbi request reprint [Orthopedic manifestations of the antiphospholipid syndrome]
    E Rosenthal
    Service de médecine interne cancérologie, hôpital de l Archet 1, 151, Route de Saint Antoine de Ginestiere, 06200 Nice, France
    Rev Med Interne 28:103-7. 2007
  6. ncbi request reprint [Visceral leishmaniases]
    Eric Rosenthal
    Service de Medecine Interne, Hopital de l Archet, CHU de Nice, 06202 Nice cedex
    Rev Prat 54:2211-6. 2004
  7. ncbi request reprint Recent understanding in the treatment of visceral leishmaniasis
    E Rosenthal
    Service d Hematologie Clinique, Hopital L Archet, Centre Hospitalier Universitaire de Nice, 06202 Nice Cedex 02, France
    J Postgrad Med 49:61-8. 2003
  8. ncbi request reprint HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania
    E Rosenthal
    Department of Internal Medicine Hematology, Nice University Hospital, Nice, France
    Clin Infect Dis 31:1093-5. 2000
  9. ncbi request reprint Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C
    P Cacoub
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, Paris, France
    Medicine (Baltimore) 79:47-56. 2000
  10. ncbi request reprint [Disseminated Penicillium marneffei infection suggesting visceral leishmaniasis in an HIV infected patient]
    E Rosenthal
    Service d Hematologie Clinique, Hopital Archet 2, Nice
    Presse Med 29:363-4. 2000

Detail Information

Publications36

  1. pmc Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)
    Dominique Salmon-Ceron
    Unité de maladies infectieuses, Pôle Médecine, Hopital Cochin, Paris, France
    BMC Health Serv Res 12:59. 2012
    ..Treatment for the hepatitis C virus (HCV) may be delayed significantly in HIV/HCV co-infected patients. Our study aims at identifying the correlates of access to HCV treatment in this population...
  2. pmc The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010
    Marc Arthur Loko
    INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
    BMC Infect Dis 10:303. 2010
    ..The ANRS CO 13 HEPAVIH cohort was set up to explore these critical questions.To describe the cohort aims and organization, monitoring and data collection procedures, baseline characteristics, as well as follow-up findings to date...
  3. doi request reprint [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009]
    E Rosenthal
    Service de Medecine Interne, centre hospitalier universitaire de Nice et université de Nice Sophia Antipolis, France
    Med Mal Infect 39:741-4. 2009
    ..In Europe, liposomal amphotericin B has progressively become the reference treatment of VL in clinical practice, and it is recommended as the first line therapy...
  4. doi request reprint Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19)
    E Rosenthal
    Department of Internal Medicine, Archet Hospital Centre, University of Nice Sophia Antipolis, Nice, France
    HIV Med 10:282-9. 2009
    ..More than 10 years after the introduction of combination antiretroviral therapy (cART), we examined the trend in the proportion of deaths caused by end-stage liver disease (ESLD) in HIV-infected adults in France between 1995 and 2005...
  5. ncbi request reprint [Orthopedic manifestations of the antiphospholipid syndrome]
    E Rosenthal
    Service de médecine interne cancérologie, hôpital de l Archet 1, 151, Route de Saint Antoine de Ginestiere, 06200 Nice, France
    Rev Med Interne 28:103-7. 2007
    ..We briefly discuss postulated pathogenesis and possible implications of anticoagulation...
  6. ncbi request reprint [Visceral leishmaniases]
    Eric Rosenthal
    Service de Medecine Interne, Hopital de l Archet, CHU de Nice, 06202 Nice cedex
    Rev Prat 54:2211-6. 2004
    ..Elsewhere, pentavalent antimonials remain the cornerstone of treatment in non resistant areas, conventional amphotericin B or miltefosine being an alternative in areas of resistance to antimony...
  7. ncbi request reprint Recent understanding in the treatment of visceral leishmaniasis
    E Rosenthal
    Service d Hematologie Clinique, Hopital L Archet, Centre Hospitalier Universitaire de Nice, 06202 Nice Cedex 02, France
    J Postgrad Med 49:61-8. 2003
    ..Here, we recommend different treatment schedules according to the resistance pattern and the region-specific socio-economical and cultural factors...
  8. ncbi request reprint HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania
    E Rosenthal
    Department of Internal Medicine Hematology, Nice University Hospital, Nice, France
    Clin Infect Dis 31:1093-5. 2000
    ..In such patients, the involvement of atypical locations may lead to the discovery of VL...
  9. ncbi request reprint Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C
    P Cacoub
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, Paris, France
    Medicine (Baltimore) 79:47-56. 2000
    ..Cryoglobulin positivity is associated with systemic vasculitis and rheumatoid factor and HIV positivity. HIV coinfection is associated with arthralgia or myalgia, anticardiolipin antibodies, and thrombocytopenia...
  10. ncbi request reprint [Disseminated Penicillium marneffei infection suggesting visceral leishmaniasis in an HIV infected patient]
    E Rosenthal
    Service d Hematologie Clinique, Hopital Archet 2, Nice
    Presse Med 29:363-4. 2000
    ..Penicilliosis is a fungal infection caused by Penicillium marneffei. In Southeast Asia, this infection is common in HIV-infected patients but few cases have been reported in Europe...
  11. ncbi request reprint Clinical manifestations of visceral leishmaniasis associated with HIV infection: a retrospective study of 91 French cases
    E Rosenthal
    Department of Internal Medicine Haematology, Sophia Antipolis University, Nice, France
    Ann Trop Med Parasitol 94:37-42. 2000
    ..Overall, VL diagnosis was fortuitous in 27% of the subjects. Even in endemic areas, therefore, VL is not considered routinely by physicians attempting diagnoses...
  12. ncbi request reprint Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study)
    E Rosenthal
    Department of Internal Medicine, hôpital de l Archet 1, Nice, France
    J Viral Hepat 14:183-8. 2007
    ..4%) than in 2001 (26.3%). Seven years after the introduction of HAART, ESLD associated with HCV infections is a leading cause of mortality in HIV-infected patients, which did not increase between the years 2001 and 2003...
  13. doi request reprint [HIV and hepatitis C virus coinfection]
    P Cacoub
    Service de Medecine Interne, AP HP, hôpital La Pitié Salpêtrière, 83, Bd de l Hopital, 7 5651 Paris cedex 13, France
    Gastroenterol Clin Biol 32:S82-9. 2008
    ..Effective management strategies that encompass patient and viral factors are necessary to improve the long-term outlook for coinfected patients...
  14. ncbi request reprint A century of leishmaniasis in Alpes-Maritimes, France
    P Marty
    Equipe de Recherche sur les Leishmanioses, Faculte de Medecine, 28, Avenue de Valombrose, 06107 Nice Cedex 2, France
    Ann Trop Med Parasitol 101:563-74. 2007
    ..Recently, it has been demonstrated that, in Alpes-Maritimes, approximately 20% of those found seropositive in leishmanin skin tests are asymptomatic carriers, with amastigotes in their peripheral blood...
  15. doi request reprint [Leishmaniases in France: an update]
    P Marty
    Service de Parasitologie Mycologie, Centre Hospitalier Universitaire L Archet, BP 3079, 062002 Nice cedex 3
    Arch Pediatr 16:S96-100. 2009
    ..Serological tests are useful, but the diagnosis is made by the identification of the parasite in a bone marrow sample. Today, the treatment is done by the liposomal amphotericin B (AmBisome) and the total dose must to be 20 mg/kg...
  16. ncbi request reprint Treatment of visceral leishmaniasis: a review of current treatment practices
    Pierre Marty
    Groupe de Recherche en Immunopathologie de la Leishmaniose, Faculte de Medecine, Université de Nice Sophia Antipolis et Service de Parasitologie Mycologie, Centre Hospitalier Universitaire de Nice, Hopital de l Archet, Nice, France
    Expert Opin Pharmacother 3:1101-8. 2002
    ..The prohibitive cost of new therapies leads to different treatment practices according to the socioeconomic and cultural status of each region...
  17. pmc Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients
    Laure Valerio
    Departement de sante publique, Centre Hospitalier Universitaire de Nice, Nice, France
    J Acquir Immune Defic Syndr 47:50-5. 2008
    ..Our objective was to determine if a baseline CD4 count >/=350 cells/mm predicts a sustained HCV response to pegylated interferon plus ribavirin...
  18. doi request reprint Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children
    Amandine Rubio
    Service de Physiologie et Explorations Fonctionnelles Pédiatriques, Pôle Enfants Adolescents, CHU de Nice et Université de Nice Sophia Antipolis, UFR de Medecine, France
    J Pediatr Gastroenterol Nutr 49:599-606. 2009
    ....
  19. pmc Convenience of serum for visceral leishmaniasis diagnosis by PCR
    Cristel Fissore
    Equipe de Recherche sur les Leishmanioses, Universite de Nice Sophia Antipolis, Nice, France
    J Clin Microbiol 42:5332-3. 2004
    ..In the case of primary diagnosis of MVL, the serum PCR showed a sensitivity of 97% and a specificity of 95%, with positive and negative predictive values of 94 and 97%, respectively...
  20. doi request reprint Prevalence, characteristics and prognostic significance of anemia in daily practice
    B Terrier
    Department of Internal Medicine, APHP Groupe Hospitalier Pitié Salpé trière, Universite Pierre et Marie Curie, Paris 6, Paris, France
    QJM 105:345-54. 2012
    ..The prevalence of anemia has been studied in well-defined populations, but no large study is available for less restricted populations with various disorders...
  21. ncbi request reprint Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)
    Eric Rosenthal
    Service d Hematologie Clinique, Hopital Archet, Nice, France
    AIDS 17:1803-9. 2003
    ....
  22. ncbi request reprint Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia
    P Cacoub
    Department of Internal Medicine, , Paris, France
    Arthritis Rheum 44:2118-24. 2001
    ..In contrast, HLA-DR7 appears to protect against the production of type II MC. These results suggest that the host's immune response genes may play a role in the pathogenesis of HCV-associated MC...
  23. ncbi request reprint Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma
    Eric Rosenthal
    Service d Hématologie Clinique and G E R C B T, hôpital Archet 1, 151 route de Saint Antoine de Ginistière, 06200 Nice, France
    Am J Clin Oncol 25:57-9. 2002
    ..Our study confirms that daunorubicin is effective in patients with advanced KS. Daunorubicin is well tolerated over the long term in association with HAART...
  24. ncbi request reprint Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    J Hepatol 48:35-42. 2008
    ..To analyze the barriers to HCV treatment in HIV-HCV co-infected patients and their evolution between 2004 and 2006...
  25. ncbi request reprint Liposomal amphotericin B for the treatment of visceral leishmaniasis
    Caryn Bern
    Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Infect Dis 43:917-24. 2006
    ..The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs...
  26. ncbi request reprint Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment
    Firouzé Bani-Sadr
    INSERM U707, Faculte de Medecine Hopital Saint Antoine, Paris, France
    Clin Infect Dis 41:1806-9. 2005
    ..02), and elevated total bilirubin level (OR, 7.9; 95% CI, 1.08-93.3; P<.03). Didanosine should thus not be given to patients with cirrhosis, particularly when treatments for HCV and HIV infections have to be administered concomitantly...
  27. ncbi request reprint Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, France
    J Acquir Immune Defic Syndr 40:47-52. 2005
    ..To evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy...
  28. doi request reprint Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin
    Firouzé Bani-Sadr
    AIDS 22:1385-7. 2008
  29. ncbi request reprint Visceral leishmaniasis in organ transplant recipients: 11 new cases and a review of the literature
    Didier Basset
    Laboratoire de Parasitologie Mycologie and Centre National de Référence des Leishmania, CHU de Montpellier, 163, Rue Auguste Broussonet, 34090 Montpellier, France
    Microbes Infect 7:1370-5. 2005
    ..Treatment using either antimonials or amphotericine B gave similar cure rates of around 80% of the cases. But toxicity was higher for antimonials. Relapses occurred in 14.3%...
  30. ncbi request reprint Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial
    Fabrice Carrat
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, Paris, France
    JAMA 292:2839-48. 2004
    ..Most data on the virologic efficacy and safety of the combination of peginterferon alfa-2b and ribavirin in coinfected patients come from uncontrolled studies...
  31. doi request reprint Risk factors for grade 3 or 4 gamma-glutamyl transferase elevation in HIV/hepatitis C virus-coinfected patients
    Firouzé Bani-Sadr
    AIDS 22:1234-6. 2008
  32. ncbi request reprint [Management of HCV-HIV patients]
    Stanislas Pol
    Unité d Hépatologie, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris
    Gastroenterol Clin Biol 31:4S7-12. 2007
    ..The harmful impact of HIV underlines the need for improving:..
  33. ncbi request reprint Patients know it: Hughes syndrome is unique
    Eric Rosenthal
    J Rheumatol 33:1919-20. 2006
  34. ncbi request reprint Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement
    Sophie Grabar
    Service de Biostatistique et Informatique Médicale, Hopital Cochin, Paris, France
    J Clin Oncol 24:3408-14. 2006
    ..To study the impact of different potent combined antiretroviral treatment (cART) on the incidence of HIV-associated Kaposi's sarcoma (KS) with and without visceral involvement...
  35. ncbi request reprint Cardiac magnetic resonance imaging after stage I Norwood operation for hypoplastic left heart syndrome
    Vivek Muthurangu
    Cardiac MR Research Group, Division of Imaging Sciences, King s College London, United Kingdom
    Circulation 112:3256-63. 2005
    ..In this study, we describe the results of 37 patients who underwent cardiovascular magnetic resonance (MR) assessment before BCPC...
  36. ncbi request reprint Cytology of peritoneal leishmaniasis in a patient with AIDS
    Olivier Oregioni
    Acta Cytol 47:98-9. 2003